Back HBV Prevention HBV Vaccines

HBV Vaccines

Gilead and GlobeImmune Will Collaborate on Hepatitis B Therapeutic Vaccine

Gilead Sciences and GlobeImmune announced this week that they will collaborate on the development and commercialization of a hepatitis B virus (HBV) therapeutic vaccine using GlobeImmune's Tarmogen yeast vector technology. In contrast to widely used HBV preventive vaccines, therapeutic vaccines are designed to stimulate the body's immune response to the virus, and may be used in conjunction with oral antiviral drugs. alt

Read more:

ICAAC 2011: Double Dose of Hepislav Works as Well as 3 Doses of Standard HBV Vaccine

Two injections of Dynavax's investigational Heplisav hepatitis B virus (HBV) vaccine protected adults over age 40 as well as the standard regimen consisting of 3 doses of the Engerix-B vaccine given over 6 months, researchers reported at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) last month in Chicago.alt

Read more:

Hepatitis B Vaccination Dramatically Lowers Prevalence among U.S. Children

Children and adolescents in the U.S. today have a very low likelihood of hepatitis B virus (HBV) infection thanks to widespread vaccination, according to an epidemiological study described in the March 1, 2011, Annals of Internal Medicine. Many adults remain vulnerable, however, underlining the importance of vaccination for at-risk groups. alt

Read more:

Additional HBV Vaccine Dose Offers More Protection for People with HIV

Two alternative dosing schedules of hepatitis B virus (HBV) vaccination led to higher levels of protection than the standard 3-dose schedule. alt

Read more:

Hepatitis B Therapeutic Vaccine Appears Safe and Stimulates Immune Response

In late December, Dynavax Technologies reported findings from a small early clinical trial showing that its investigational hepatitis B virus (HBV) therapeutic vaccine DV-601 -- intended to help control the virus in people already infected, rather than prevent infection -- was well tolerated and produced immunological and virological responses at all dose levels. Larger studies are needed, however, to show whether the vaccine is clinically effective.

Read more: